Neiburger R G, Youmans G P, Youmans A S
Infect Immun. 1973 Jul;8(1):42-7. doi: 10.1128/iai.8.1.42-47.1973.
The migration inhibition technique has been used to study delayed hypersensitivity in vitro by using peritoneal exudate cells and splenic lymphocytes from mice vaccinated with viable cells of the attenuated H37Ra strain of Mycobacterium tuberculosis and from mice vaccinated with ribonucleic acid (myc RNA) preparations obtained from viable mycobacterial cells of the same strain. Inhibition of macrophage migration was noted when purified protein derivative (PPD) or viable H37Ra cells were added to peritoneal exudate cells obtained from mice immunized with viable H37Ra cells and not from mice immunized with myc RNA. Splenic lymphocyte cultures were exposed to the same antigens in vitro. Filtered supernatant fluids from these lymphocyte cultures, when added to peritoneal exudate cells obtained from nonimmunized mice, inhibited migration only when they were obtained from lymphocytes which came from mice immunized with viable H37Ra cells. Injection of PPD intravenously into vaccinated mice resulted in inhibitory supernatant fluids from splenic lymphocyte cultures only when the lymphocytes came from mice immunized with viable H37Ra cells. However, intravenous injection of either viable H37Ra cells or of myc RNA preparations into mice vaccinated with myc RNA occasionally produced inhibitory supernatant fluids when lymphocytes were obtained from these mice. On the other hand, mice vaccinated with myc RNA or viable H37Ra cell preparations were consistently and equally protected against intravenous challenge with the virulent H37Rv strain. Thus, although some evidence was obtained for a delayed type hypersensitivity in mice vaccinated with H37Ra cells or with myc RNA to ribosomal proteins or other proteins associated with the RNA preparation, no evidence of tuberculin hypersensitivity could be detected in any mice vaccinated with the myc RNA. These results argue against a role for tuberculin hypersensitivity in immunity to tuberculous infection.
迁移抑制技术已被用于体外研究迟发型超敏反应,所用细胞为:接种减毒结核分枝杆菌H37Ra株活细胞的小鼠的腹腔渗出细胞和脾淋巴细胞,以及接种从同一菌株活分枝杆菌细胞获得的核糖核酸(myc RNA)制剂的小鼠的腹腔渗出细胞和脾淋巴细胞。当将纯化蛋白衍生物(PPD)或活的H37Ra细胞添加到从接种活H37Ra细胞的小鼠而非接种myc RNA的小鼠获得的腹腔渗出细胞中时,可观察到巨噬细胞迁移受到抑制。脾淋巴细胞培养物在体外暴露于相同抗原。这些淋巴细胞培养物的过滤上清液,当添加到从未免疫小鼠获得的腹腔渗出细胞中时,只有当它们来自接种活H37Ra细胞的小鼠的淋巴细胞时才会抑制迁移。仅当淋巴细胞来自接种活H37Ra细胞的小鼠时,向接种疫苗的小鼠静脉注射PPD才会导致脾淋巴细胞培养物产生抑制性上清液。然而,当从这些小鼠获得淋巴细胞时,向接种myc RNA的小鼠静脉注射活的H37Ra细胞或myc RNA制剂偶尔会产生抑制性上清液。另一方面,接种myc RNA或活H37Ra细胞制剂的小鼠对强毒H37Rv菌株的静脉攻击始终具有同等程度的保护作用。因此,尽管在用H37Ra细胞或myc RNA接种的小鼠中获得了一些证据,表明对核糖体蛋白或与RNA制剂相关的其他蛋白存在迟发型超敏反应,但在任何接种myc RNA的小鼠中均未检测到结核菌素超敏反应的证据。这些结果表明结核菌素超敏反应在结核感染免疫中不起作用。